Geron Co. (NASDAQ:GERN) has been assigned a consensus rating of “Hold” from the eight analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $3.42.

Several equities analysts recently commented on the stock. Zacks Investment Research cut shares of Geron from a “hold” rating to a “sell” rating and set a $1.50 target price for the company. in a research note on Tuesday. ValuEngine upgraded shares of Geron from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. BidaskClub cut shares of Geron from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 1st. B. Riley began coverage on shares of Geron in a research note on Tuesday, November 19th. They issued a “buy” rating and a $4.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $3.00 price objective on shares of Geron in a research note on Monday, December 23rd.

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Geron by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 9,644,900 shares of the biopharmaceutical company’s stock valued at $13,599,000 after buying an additional 141,384 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Geron by 3.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,080,623 shares of the biopharmaceutical company’s stock valued at $1,524,000 after buying an additional 31,448 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Geron by 11.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 805,331 shares of the biopharmaceutical company’s stock valued at $1,135,000 after buying an additional 79,827 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Geron by 60.8% in the 3rd quarter. SG Americas Securities LLC now owns 354,980 shares of the biopharmaceutical company’s stock valued at $472,000 after buying an additional 134,245 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Geron by 9.5% in the 3rd quarter. Rhumbline Advisers now owns 274,615 shares of the biopharmaceutical company’s stock valued at $365,000 after buying an additional 23,882 shares in the last quarter. Institutional investors own 29.74% of the company’s stock.

NASDAQ:GERN traded down $0.04 during trading hours on Friday, hitting $1.41. 1,262,902 shares of the company traded hands, compared to its average volume of 1,368,250. The stock has a market capitalization of $289.68 million, a price-to-earnings ratio of -5.64 and a beta of 2.28. Geron has a twelve month low of $0.99 and a twelve month high of $2.14. The firm has a 50-day moving average of $1.42 and a 200 day moving average of $1.39.

Geron (NASDAQ:GERN) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.10 million. Geron had a negative net margin of 7,044.88% and a negative return on equity of 29.22%. During the same period in the prior year, the company earned $0.24 EPS. On average, analysts expect that Geron will post -0.42 EPS for the current year.

Geron Company Profile

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Further Reading: How is the LIBOR rate calculated?

Analyst Recommendations for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.